Efficacies of bevacizumab-related therapies in recurrent high-grade glioma: a single-center study
10.3760/cma.j.cn115354-20200809-00636
- VernacularTitle:贝伐珠单抗相关治疗对复发性高级别胶质瘤患者疗效的单中心研究
- Author:
Wenlin CHEN
1
;
Ziren KONG
;
Wenbin MA
;
Yu WANG
Author Information
1. 中国医学科学院北京协和医学院，北京协和医院神经外科 100730
- Keywords:
Glioma;
Bevacizumab;
Progression-free survival;
Overall survival
- From:
Chinese Journal of Neuromedicine
2021;20(2):153-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacies of bevacizumab monotherapy and combination therapy of bevacizumab with irinotecan, semustine and cisplatin in patients with recurrent high-grade glioma.Methods:Seventy patients with recurrent high-grade glioma admitted to our hospital from January 2011 to November 2019 were chosen in our study; 38 patients received bevacizumab monotherapy, 13 patients accepted bevacizumab and semustine combination therapy, 11 patients received bevacizumab and cisplatin combination therapy, and 8 patients accepted bevacizumab and irinotecan combination therapy. Survival statuses (progression-free survival [PFS] and overall survival [OS]) of these patients were retrospectively analyzed.Results:The median OS and median PFS of the enrolled patients were 12.83 months and 6.23 months, respectively. The median OS and median PFS of patients accepted bevacizumab monotherapy were 10.92 months and 5.03 months, respectively. The median OS and median PFS of patients accepted bevacizumab and semustine combination therapy were 16.30 months and 6.77 months, respectively. The median OS in patients accepted bevacizumab and irinotecan combination therapy and patients accepted bevacizumab and cisplatin combination therapy was 11.90 months and 14.40 months, respectively.Conclusion:Bevacizumab by different therapy methods enjoys good efficacy; bevacizumab monotherapy or combination therapy can be recommended for recurrent high-grade glioma.
